HOPHF Stock Price, Chart, Stats & News

Hemogenyx Pharmaceuticals Plc
Save
Hemogenyx Pharmaceuticals Plc (HOPHF) does not currently pay a dividend.
15.84M
Market cap
–
Current P/E
–
Forward P/E
HOPHF chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market innovative therapies for various blood-related diseases. The company's pipeline includes several promising candidates tailored for the bone marrow/hematopoietic stem cell (BM/HSC) transplant market. These include a CDX bi-specific antibody designed to target relapsed/refractory acute myeloid leukemia (R/R AML), certain forms of acute lymphoblastic leukemia, and myelodysplastic syndrome.
Similar securities
Based on sector and market capitalization
Report issue





